Selegiline (HCl)

Selegiline (HCl) is a selective inhibitor of monoamine oxidase B. Selegiline (HCl) is used along with levodopa in the management of Parkinson's disease. It inhibits the breakdown of dopamine in the brain and prolongs the action of Levodopa

Selegiline (HCl) is primarily indicated in conditions like Parkinson disease.

Selegiline (HCl) is contraindicated in conditions like Psychosis, Extrapyramidal disorders, Huntington's disease.

The symptomatic adverse reactions produced by Selegiline (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Nausea, Diarrhea, Palpitation, Abdominal pain, Confusion, Malaise, Weight loss, Anemia, Dyskinesia, Urinary retention, Arrhythmias, Generalized pain, Hallucinations, HTN, Insomnia, Mood changes, Syncope, Orthostatic hypotension, Suicidal thoughts and behaviors, Serotonin syndrome.

Selegiline should be used with caution in patients with peptic ulcer and of allergies, especially of drug allergies. Rarely, this can cause headache and increased blood pressure when tyramine containing foods are ingested, consult the doctor about the use of diet containing tyramine (e.g. meat, fish, pickle, liver, dry sausage, meat prepared with tenderizer, yogurt, cheese, beverages, cheery, excessive amounts of caffeine, bananas, figs, raisins, broad beans, soy sauce, chocolate). Caution regarding food should be continued at least 2 weeks after discontinuing use of this drug. This drug should be used during pregnancy only if clearly needed.

Drug should not be given to Pediatrics, Pregnant Mothers, Geriatrics, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

5 to 10 mg (7.5 (7.5)) 24 hourly PO —

Not applicable in paeds ( ) —

Not applicable in this age group ( ) —

Selegiline (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlbuterolShould not use concurrently without doctors prescription.Amantadine (HCl)Butorphanol (Tartrate)CarbamazepineConcomitant use of carbamazepine and monoamine oxidase inhibitors (e.g. selegiline, tranylcypromine) increases the incidence of cardiac arrythmias.cyclobenzaprine hydrochlorideCoadministration of monoamine oxidase inhibitors (MAOIs) and dibenzazepine derivatives (e.g., tricyclic and tetracyclic antidepressants, cyclobenzaprine, carbamazepine) may rarely produce significant adverse reactions including nausea, vomiting, flushing, dizziness, tremor, myoclonus, rigidity, diaphoresis, hyperthermia, autonomic instability, hypertensive crises, disseminated intravascular coagulation, severe convulsive seizures, coma, and death. The exact mechanism is unknown but may be related to excessive serotonergic activity in the CNS (i.e. serotonin syndrome).MajorIn general, dibenzazepine derivatives should not be used concurrently with MAOIs or other agents that possess MAOI activity. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with tricyclic antidepressants, and vice versaDoxapramBoth agents acts synergistically in inducing sympathomimetic effect. Selegiline increases the storage of norepinephrine in adrenergic neurons and doxapram enhance liberation or reduce reuptake of catecholamines thus precipitate severe hypertension.MajorCoadministration is considered contraindicated. There should be gap of atleast 14 days between discontinuing of therapy with selegiline and initiation of treatment with doxapram.EphedrineFluoxetine (HCl)Maprotiline (HCl)Coadministration produce significant adverse reactions due to excessive serotonergic activity in the CNS i.e. serotonin syndrome.MajorCoadministration of these agents is considered contraindicated.There should be a gap of at least 14 days between initiation of treatment with maprotiline and discontinuation of maprotiline. Coadministration of these agents is considered contraindicated.There should be a gap of at least 14 days between initiation of treatment with maprotiline and discontinuation of maprotiline.MethyldopaThe combined use of methyldopa and selegiline may increases sympathetic stimulation in central nervous system result in loss of control on blood pressure, hyperexcitability and hallucination.MajorCoadministration is considered contraindicated. Start treatment with methyldopa after stopping (atleast 14 days) of selegiline.OxypertineTheoretical potential for OXYPERTINE increasing the CNS STIMULANT effect of SELEGILINEMajorParoxetineSelegiline potentiate the pharmacological activity of paroxetine thus increases the risk of serotonin syndrome.MajorCombination should be avoided. Start treatment with paroxetin after atleast 14 days of discontinuing selegiline.PergolidePethidine (HCl)PhenylalanineSelegiline may increase the antidepressant effects of phenylalanine. Phenylalanine should not be taken at the same time as selegine.PropylhexidrinePotential for enhanced sympathomimetic effects. Use concomitantly with caution.RizatriptanRizatriptan should not be used within 2 weeks of having used Selegiline (HCl).SalmeterolAction of salmeterol on the vascular system may be potentiated by Selegiline (HCl). Tetrahydrozoline (HCl)Concurrent use may increase the hypertensive effect.Vortioxetineincrease toxicity of vortioxetinenever use combination These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store in a well closed container, Below 40°C.